Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
30 results loaded, newest first. More results are available. The latest changes are still being indexed. Try again shortly for updated results.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 50,936.24 while the NASDAQ rose 0.37% to 26,960.69. The S&P 500 also rose, gaining, 0.30% to 7,674.30. Leading and Lagging Sectors Energy shares jumped by 1.3% on Thursday. In tr
The S&P 500 slipped at midday Thursday as Micron Technology Inc. (NASDAQ: MU ) fell 1.6% despite a record quarter, with the 10-year Treasury yield hovering near 5.25% and oil climbing back above $92. Micron reported fiscal fourth-quarter revenue above $54 billion and guided first-quarter revenue to $61.5 billion, but t
U.S. stocks look set to open on a mixed note on Thursday, with futures of the Dow Jones and S&P 500 indices falling, while the Nasdaq 100 futures rose, following Wednesday’s mixed close. Iran announced receiving a U.S. response regarding a proposal to restore the collapsed Gulf ceasefire as final U.S. troops completed
U.S. stocks are higher at midday Wednesday, led by technology and software shares, after softer-than-expected inflation data eased fears of another Federal Reserve rate hike. Oil is climbing again, however, and long-dated Treasury yields remain close to multi-decade highs. • United Therapeutics stock is charging ahead
The company said it will present two posters on its deupirfenidone program at the IPF Summit in Boston on Sept. 29-Oct. 1, 2026. It said SURPASS-IPF is a global Phase 3 head-to-head trial of deupirfenidone versus pirfenidone in about 1,100 adults with idiopathic pulmonary fibrosis.
Niagen Bioscience (NASDAQ: NAGE ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Niagen Bioscience Inc. reported
Three-month copper on LME up 0.2% to $14,465/mt by 0930 GMT, aiming for a ~1.2% monthly rise as China manufacturing PMI returns to growth; stocks in Shanghai warehouses fall 17.8% to 38,744 tons.
Aura Energy Limited says it has released its corporate governance statement for the year ended 30 June 2026 and filed Appendix 4G with the ASX. The board approved the statement, which was accurate and up to date as at 30 September 2026.
The company said its annual report and audit report are available on its website. It also outlined project work on the Maalinao-Caigutan-Biyog copper-gold project, management changes and a ~A$9.3 million equity raising.
The panel listed additions, deletions and other amendments to its disclosure table across several live offer periods, including Harworth Group, SThree and easyJet.
Genentech said the U.S. FDA accepted its New Drug Application for fenebrutinib under priority review for relapsing and primary progressive multiple sclerosis. The filing is based on three Phase III studies, including FENhance 1 and 2 and FENtrepid.
The company said its programme at the 35th European Academy of Dermatology and Venereology Congress in Vienna includes more than 20 abstracts, late-breaking data and two expert symposia. It highlighted new evidence for lebrikizumab, tildrakizumab, CAL/BDP PAD cream and tirbanibulin across atopic dermatitis, psoriasis a
Three-month LME copper rose 0.23% to $14,471/ton by 0330 GMT, while SHFE November gained 0.21% to 109,530 yuan ($16,340.20) after China PMIs improved; trade stayed subdued ahead of the Sept. 30 long holiday.
The TAIEX, Taiwan’s benchmark stock index, rose 615 points, or 1.3%, to a new record high of 48,247 in Wednesday morning trade, halting losses in the previous two sessions, mainly boosted by gains in electronic technology following a rise in the Philadelphia Semiconductor Index. Electronic Technology gained 1.5%, with
The company said cash collected from paid early access programs was €6.5 million and net cash used in operating activities fell 37% to €1.6 million. It also said manufacturing technology transfer to Catalent was completed and REVISE remains on track for a December 2026 last patient.
Axos Financial said it will host a conference call on October 29 at 5:00 PM ET to discuss first quarter fiscal 2027 results ended September 30, 2026. The company plans to distribute its earnings results after 4:00 PM ET the same day.
The panel's disclosure table adds or amends entries for several UK takeover situations, including Tribal Group, Vesuvius, Gamma Communications and SThree. It also lists updates for 80 Mile, Advanced Medical Solutions, Aptitude Software, Ashtead Technology, Beazley, Bodycote, CAB Payments, Capricorn Energy, Dianomi, eas
Sonova ranked first among the top 100 large companies in the latest Switzerland's Top Innovative Companies ranking by BILANZ, PME and Statista. The company said the ranking highlighted its AI-powered hearing technology and newer Phonak hearing-aid portfolio.
Bitcoin (CRYPTO: BTC) has pulled back to $84,000 over the last week, but the real test is yet ahead in light of rising Treasury yields, according to a Binance Research note published Monday. Brent crude topped $103 on Sept. 23, while PMI data hit a 62-month high. A weak 5-year Treasury auction then pushed October rate
RSA said its Agent ID platform is designed to discover, secure and govern AI agents for finance, government and other regulated industries. It also said a full air-gapped, self-managed version is planned for 2027.
Philip Morris Intl (NYSE: PM ) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Philip Morris Intl repor
The panel's 29 September 2026 disclosure table adds Vesuvius plc and RHI Magnesita N.V. as an offeree and offeror pair. It also lists several other offer periods and amendments, including Tribal Group, Gamma Communications and easyJet.
For best results when printing this announcement, please click on link below: E3 Lithium Provides Status Update on Clearwater Project Recent financing and federal funding advance Phase 3 of the Demonstration Facility as FEED, Feasibility Study, and offtake discussions progress in parallel E3 LITHIUM LTD. (TSXV: ETL) (F
The Takeover Panel updated its disclosure table with additions and amendments including Tribal Group plc, Jenzabar, Inc and other named offerors. It also lists offer periods, Rule 2.6 deadlines and related offer details for several companies.
(Adds more Katayama comments, context) By Makiko Yamazaki TOKYO, Sept 29 (Reuters) — Japanese Finance Minister Satsuki Katayama said on Tuesday she made it clear to US Treasury Secretary Scott Bessent during a phone call last week that Prime Minister Sanae Takaichi is not a reflationist. "I explained that Prime Ministe
General Dynamics Corp. (NYSE: GD ) has long been treated as one of the steadiest names in defense, but a new Wall Street warning about borrowing costs is putting its balance sheet in the spotlight. GD stock is moving. See the chart and price action here. Piper Sandler named the Gulfstream jet maker and submarine builde
Final disclosure table lists deletions across several UK takeover situations, including Bodycote, Checkit, SThree and easyJet. It also updates offeror and offeree details for other named companies.
For best results when printing this announcement, please click on link below: Cabbacis Reports First Half 2026 Financial Results and Provides Corporate Update Cabbacis (OTCQB: CABI ( ) ), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBLEND™ and X95™
The U.S. FDA accepted Bayer’s supplemental New Drug Application for Lynkuet and granted Priority Review for a new indication in women receiving endocrine therapy for breast cancer. The filing is based on Phase III OASIS-4 data.
The event will cover 52-week Phase 3 open-label extension data from China and an update on the planned U.S. AURORA Phase 3 acne trial. Sagimet targets U.S. AURORA trial initiation for Q4 2026.